Welcome to The Catalyst
Change isn't quick. Unless it's when you experience Intravascular Lithotripsy (IVL) for the first time. Stay apprised of our latest news and insights while discovering how a simple and intuitive tool can be The Catalyst to change the way you think about calcium modification.
Dr. Ehrin Armstrong presented the interim results from the first 752 patients in the Disrupt PAD III Observational Study (OS), reinforcing the consistency of IVL's unique mechanism of action to safely and effectively modify superficial and deep calcium across multiple vessel beds, lesion types and CLI patients.
Topics: Peripheral IVL, DISRUPT PAD, Peripheral Cases, Peripheral Conferences, Peripheral Clinical Data
If you are attending VIVA21, you may not be dealing cards, but you’re likely dealing with peripheral artery calcium. So join Dr. Sahil Parikh, Dr. Ehrin Armstrong, Dr. Venita Chandra and Dr. Peter Soukas at 12pm Pacific Time on Wednesday, October 6th in the Bandol Room to make sure you don’t gamble with your calcium strategy. Listen to the esteemed panel during the Shockwave Medical Symposium and you learn how Intravascular Lithotripsy (IVL) can help you beat the odds.
Topics: Peripheral IVL, DISRUPT PAD, Peripheral Cases, Peripheral Conferences, Peripheral Clinical Data
Learn about IVL’s unique mechanism of action in fracturing severe, superficial and deep calcium and the clinical outcomes associated with IVL in the coronary and peripheral vasculature.
Topics: DISRUPT CAD, IVL Technology, DISRUPT PAD, Coronary Clinical Data, Peripheral Clinical Data
“I think this is going to work!”
Topics: IVL Technology, Coronary Clinical Data, Peripheral Clinical Data
From Data to Daily Practice; Disrupting Calcium with IVL across multiple vessel beds.
Topics: Medical Meetings, Peripheral IVL, DISRUPT PAD, Peripheral Conferences, Peripheral Clinical Data
The treatment of calcified below-the-knee (BTK) lesions is challenging, associated with sub-optimal procedural outcomes, resulting in early recoil, and may contribute to restenosis.
Topics: Peripheral IVL, DISRUPT PAD, Peripheral Cases, PAD Applications - BTK, PAD Applications - CLI, Peripheral Clinical Data
Following the excitement of the PAD III RCT results presented at VIVA in November, a rock star faculty of Prof. Gunnar Tepe, Prof. Thomas Zeller, Dr. Arne Schwindt and Dr. Lorenzo Patrone assembled for an incathlab session to discuss the study results and how IVL offers superior vessel preparation over conventional PTA in severely calcified PAD lesions.
Topics: Peripheral IVL, DISRUPT PAD, Peripheral Clinical Data
At the recent PCR Valves eCourse (aka London Valves), an esteemed faculty reported on the use of IVL- facilitated TAVI. Profs./Drs. Carlo Di Mario, Ole De Backer, Joachim Schofer, Constantin von zur Mühlen used published data and case experiences to illustrate the advantages of using IVL to maintain transfemoral access in TAVI patients with severely calcified iliacs. Considering the importance of reducing complications to minimize hospital stay, the faculty expressed enthusiasm when considering the use of IVL in these very complex patients. Happy viewing!
Topics: Peripheral IVL, DISRUPT PAD, Peripheral Clinical Data
In life, and when treating patients, we all prefer things to be less complicated. Unfortunately, treating peripheral vascular calcification is typically associated with suboptimal vessel expansion and an increased risk of complications.
Topics: Peripheral IVL, DISRUPT PAD, Peripheral Clinical Data
In DISRUPT PAD III, we included the complex, torturous, calcified lesions and risky patients that other studies avoid. Review the results for yourself and see what superior looks like.
Topics: Peripheral IVL, DISRUPT PAD, Peripheral Clinical Data
But, right now we're in the early phases of the R&D program. In the meantime, don't miss the IVL application that heart teams are embracing already — maintaining transfemoral TAVR access through heavily calcified iliacs by using IVL.
